[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Bissler JJ, Kingswood JC: Renal angiomyolipomata. Kidney Int; 2004 Sep;66(3):924-34
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal angiomyolipomata.
  • Renal angiomyolipomata can exist as an imaging curiosity or represent a life-threatening condition.
  • There are likely over 10 million people world-wide who have a renal angiomyolipomata and approximately one tenth of these people also have tuberous sclerosis complex.
  • The optimum treatment of angiomyolipomata is focused on sparing renal tissue and has included no intervention, both total and partial nephrectomy, and embolization.
  • As basic science investigation into the biology of angiomyolipomata progresses, there is even hope for successful drug therapy.
  • Because these renal lesions can be associated with other organ system dysfunction, a number of medical specialists become involved in the care of affected patients.
  • The purpose of this article is to update the nephrologist on the molecular understanding of renal angiomyolipomata and for the possibilities of pharmacologic therapy in the future.
  • [MeSH-major] Angiomyolipoma / pathology. Kidney / pathology. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15327383.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA103486; United States / NIDDK NIH HHS / DK / DK61458
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 113
  •  go-up   go-down


2. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med; 2008 Jan 10;358(2):140-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
  • The drug sirolimus suppresses mTOR signaling.
  • METHODS: We conducted a 24-month, nonrandomized, open-label trial to determine whether sirolimus reduces the angiomyolipoma volume in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
  • Serial magnetic resonance imaging of angiomyolipomas and brain lesions, computed tomography of lung cysts, and pulmonary-function tests were performed.
  • The mean (+/-SD) angiomyolipoma volume at 12 months was 53.2+/-26.6% of the baseline value (P<0.001) and at 24 months was 85.9+/-28.5% of the baseline value (P=0.005).
  • At 24 months, five patients had a persistent reduction in the angiomyolipoma volume of 30% or more.
  • During the period of sirolimus therapy, among patients with lymphangioleiomyomatosis, the mean forced expiratory volume in 1 second (FEV1) increased by 118+/-330 ml (P=0.06), the forced vital capacity (FVC) increased by 390+/-570 ml (P<0.001), and the residual volume decreased by 439+/-493 ml (P=0.02), as compared with baseline values.
  • CONCLUSIONS: Angiomyolipomas regressed somewhat during sirolimus therapy but tended to increase in volume after the therapy was stopped.
  • Some patients with lymphangioleiomyomatosis had improvement in spirometric measurements and gas trapping that persisted after treatment.
  • Suppression of mTOR signaling might constitute an ameliorative treatment in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. (ClinicalTrials.gov number, NCT00457808. )
  • [MeSH-major] Angiomyolipoma / drug therapy. Immunosuppressive Agents / therapeutic use. Lung Neoplasms / complications. Lymphangioleiomyomatosis / complications. Sirolimus / therapeutic use. Tuberous Sclerosis / complications
  • [MeSH-minor] Adult. Brain / pathology. Female. Humans. Kidney Diseases / pathology. Liver Diseases / pathology. Lung / diagnostic imaging. Lung / physiopathology. Magnetic Resonance Imaging. Male. Middle Aged. Protein Kinase Inhibitors / therapeutic use. Protein Kinases / metabolism. Radiography. Respiratory Function Tests. TOR Serine-Threonine Kinases


3. Higa F, Uchihara T, Haranaga S, Yara S, Tateyama M, Oshiro Y, Shiraishi M, Kumasaka T, Seyama K, Fujita J: Malignant epithelioid angiomyolipoma in the kidney and liver of a patient with pulmonary lymphangioleiomyomatosis: lack of response to sirolimus. Intern Med; 2009;48(20):1821-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant epithelioid angiomyolipoma in the kidney and liver of a patient with pulmonary lymphangioleiomyomatosis: lack of response to sirolimus.
  • A 26-year-old woman with lymphangioleiomyomatosis (LAM) was hospitalized for the surgical excision of a giant abdominal tumor of right kidney origin.
  • The pathological diagnosis of the tumor was conventional angiomyolipoma (AML).
  • However, the drug did not inhibit the rapid growth of the tumor at all.
  • This finding suggests that sirolimus might not be effective against epithelioid AML, and in such cases, complete surgical resection should be the treatment of choice.
  • [MeSH-major] Angiomyolipoma / diagnosis. Kidney Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Lymphangioleiomyomatosis / diagnosis. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local / complications. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy


Advertisement
4. Lenci I, Angelico M, Tisone G, Orlacchio A, Palmieri G, Pinci M, Bombardieri R, Curatolo P: Massive hepatic angiomyolipoma in a young woman with tuberous sclerosis complex: significant clinical improvement during tamoxifen treatment. J Hepatol; 2008 Jun;48(6):1026-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive hepatic angiomyolipoma in a young woman with tuberous sclerosis complex: significant clinical improvement during tamoxifen treatment.
  • Since AMLs express estrogen and progesteron receptors we suggest the possible benefits of tamoxifen for the treatment of liver AMLs.
  • METHODS: We report the case of a 26-year-old female affected by tuberous sclerosis (TSC2) with cerebral, renal and hepatic involvement admitted to the Liver Unit for severe malnutrition, anorexia and abdominal pain.
  • Liver biopsy showed tumoral tissue with microscopic and ultrastructural features of angiomyolipoma.
  • RESULTS: After 6 months of tamoxifen treatment a greatly improved quality of life and a significant weight gain were observed.
  • [MeSH-major] Angiomyolipoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Liver Neoplasms / drug therapy. Tamoxifen / therapeutic use. Tuberous Sclerosis / complications
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18436329.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


5. Biecker E, Fischer HP, Strunk H, Sauerbruch T: Benign hepatic tumours. Z Gastroenterol; 2003 Feb;41(2):191-200
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to advances in imaging procedures like MRI, Cf-scan and ultrasound as well as progress in immunohistochemistry, the appropriate diagnosis is made ina high percentage of patients without laparotomy and resection.
  • Most important in clinical practice is the differential diagnosis of focal nodular hyperplasia and hepatocellular adenoma because of the risk of rupture and bleeding in the latter.
  • Cavernous haemangioma, the most common benign hepatic tumour, rarely needs treatment.
  • The diagnosis of nodular regenerative hyperplasia is often missed and patients present with secondary complications and signs of portal hypertension that necessitate treatment.
  • The main problem in angiomyolipoma is to distinguish it from malignant processes which do require treatment.
  • Therapeutic options are drug therapy or surgical resection.
  • [MeSH-major] Liver Diseases / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / pathology. Adult. Aged. Diagnostic Imaging. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / pathology. Granuloma, Plasma Cell / diagnosis. Granuloma, Plasma Cell / pathology. Hemangioendothelioma / diagnosis. Hemangioendothelioma / pathology. Hemangioma, Cavernous / diagnosis. Hemangioma, Cavernous / pathology. Humans. Infant. Liver / pathology. Liver Regeneration / physiology. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12650132.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 138
  •  go-up   go-down


6. Lesma E, Grande V, Ancona S, Carelli S, Di Giulio AM, Gorio A: Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM. PLoS One; 2008;3(10):e3558
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM.
  • We previously isolated, from an angiomyolipoma of a TSC2 patient, a homogenous population of smooth muscle-like cells (TSC2(-/-) ASM cells) that have a mutation in the TSC2 gene as well as TSC2 loss of heterozygosity (LOH) and consequently, do not produce the TSC2 gene product, tuberin.
  • Exposure of TSC2(-/-) ASM cells to rapamycin reduced the proliferation rate, but only when added at plating time.
  • [MeSH-major] Antibodies / pharmacology. Cell Proliferation / drug effects. Lymphangioleiomyomatosis / therapy. Myocytes, Smooth Muscle / drug effects. Receptor, Epidermal Growth Factor / immunology. Smooth Muscle Tumor / therapy. Tuberous Sclerosis / therapy. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Antibody Affinity. Antibody Specificity. Cells, Cultured. Female. Humans. Models, Biological. Muscle, Smooth, Vascular / drug effects. Muscle, Smooth, Vascular / metabolism. Muscle, Smooth, Vascular / pathology. Transfection

  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1999;68:913-63 [10872469.001]
  • [Cites] J Biol Chem. 2008 Feb 1;283(5):2575-85 [18056704.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):29930-7 [15150271.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94 [15342917.001]
  • [Cites] Am J Physiol. 1993 Aug;265(2 Pt 2):F239-49 [8368333.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Hum Mol Genet. 2002 Mar 1;11(5):525-34 [11875047.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30958-67 [12045200.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):648-57 [12172553.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5645-50 [12384518.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8470-6 [12466966.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):491-500 [12547707.001]
  • [Cites] Genes Dev. 2003 Jun 1;17(11):1352-65 [12782654.001]
  • [Cites] J Clin Invest. 2003 Oct;112(8):1223-33 [14561707.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Mar;286(3):G412-9 [14592948.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):812-6 [14871804.001]
  • [Cites] J Surg Res. 2000 May 1;90(1):39-44 [10781373.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2419-23 [8162590.001]
  • [Cites] Hum Genet. 1994 Oct;94(4):437-40 [7927344.001]
  • [Cites] J Biol Chem. 1995 Oct 27;270(43):25352-5 [7592698.001]
  • [Cites] Hum Mol Genet. 1998 Jun;7(6):1053-7 [9580671.001]
  • [Cites] Am J Physiol. 1998 Jul;275(1 Pt 1):G151-8 [9655695.001]
  • [Cites] Mol Med Today. 1998 Jul;4(7):313-9 [9743993.001]
  • [Cites] Cell. 1998 Oct 2;95(1):29-39 [9778245.001]
  • [Cites] J Biol Chem. 1999 Jul 16;274(29):20611-8 [10400692.001]
  • [Cites] Pediatr Res. 2005 Jan;57(1):67-75 [15557109.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):213-27 [15578690.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2474-81 [15781664.001]
  • [Cites] Cell. 2005 Apr 22;121(2):179-93 [15851026.001]
  • [Cites] Am J Pathol. 2005 Oct;167(4):1093-103 [16192644.001]
  • [Cites] Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25 [16736979.001]
  • [Cites] Mol Med. 2007 Mar-Apr;13(3-4):166-77 [17592551.001]
  • [Cites] N Engl J Med. 2008 Jan 10;358(2):140-51 [18184959.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):483-91 [11485907.001]
  • (PMID = 18958173.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Tumor Suppressor Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2570214
  •  go-up   go-down


7. Gould Rothberg BE, Grooms MC, Dharnidharka VR: Rapid growth of a kidney angiomyolipoma after initiation of oral contraceptive therapy. Obstet Gynecol; 2006 Sep;108(3 Pt 2):734-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid growth of a kidney angiomyolipoma after initiation of oral contraceptive therapy.
  • BACKGROUND: Kidney angiomyolipomas are benign but progressive tumors consisting of smooth muscle, fat, and vascular elements, commonly associated with the tuberous sclerosis complex.
  • During the 12 months of contraceptive therapy, a new 4-cm exophytic angiomyolipoma developed that required selective arterial embolization to reduce its risk of spontaneous rupture.
  • CONCLUSION: Treating menorrhagia with exogenous hormonal therapy in women with tuberous sclerosis complex should be accompanied by regular renal imaging to reduce the risk of an unanticipated angiomyolipoma-related adverse event.
  • Alternate nonhormonal therapies for menorrhagia may also be considered.
  • [MeSH-major] Angiomyolipoma / pathology. Contraceptives, Oral / adverse effects. Kidney Neoplasms / pathology. Menorrhagia / drug therapy
  • [MeSH-minor] Adolescent. Embolization, Therapeutic. Female. Humans. Tomography, X-Ray Computed. Tuberous Sclerosis / complications. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018483.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral
  •  go-up   go-down


8. Anisya-Vasanth AV, Satishchandra P, Nagaraja D, Swamy HS, Jayakumar PN: Spectrum of epilepsy in tuberous sclerosis. Neurol India; 2004 Jun;52(2):210-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis (TS) is an autosomal dominant disease that affects the brain, skin, eye, heart and kidney.
  • There are relatively few Indian studies on this disorder.
  • Patients often had more than one seizure type.
  • One patient each had retinal phakoma and renal angiomyolipoma.
  • Most patients were on combinations of anti-convulsants and response to therapy was usually not very satisfactory.
  • [MeSH-minor] Adolescent. Anticonvulsants / therapeutic use. Child. Child, Preschool. Drug Therapy, Combination. Female. Humans. Infant. Male. Mental Disorders / etiology. Skin Diseases / etiology. Vigabatrin / therapeutic use


9. Wienecke R, Fackler I, Linsenmaier U, Mayer K, Licht T, Kretzler M: Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis; 2006 Sep;48(3):e27-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.
  • A 19-year old patient with tuberous sclerosis presented with a renal angiomyolipoma.
  • Because animal trials of tuberous sclerosis showed an effect of rapamycin on renal tumors, our patient was administered rapamycin for 6 months.
  • During this time, the renal angiomyolipoma shrank significantly, regrew during an 8-month period, and decreased in size again after readministration of rapamycin.
  • [MeSH-major] Angiomyolipoma / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Kidney Neoplasms / drug therapy. Sirolimus / therapeutic use. Tuberous Sclerosis / complications
  • [MeSH-minor] Adult. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931204.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


10. Bissler JJ, Racadio J, Donnelly LF, Johnson ND: Reduction of postembolization syndrome after ablation of renal angiomyolipoma. Am J Kidney Dis; 2002 May;39(5):966-71
Hazardous Substances Data Bank. ACETAMINOPHEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of postembolization syndrome after ablation of renal angiomyolipoma.
  • Approximately 75% of patients with tuberous sclerosis complex develop renal angiomyolipomas.
  • These hamartomatous lesions distort and damage renal parenchyma and can lead to hemorrhage.
  • To reduce the risk of hemorrhage, transarterial embolization is used to necrose the angiomyolipoma while sparing normal renal tissue.
  • Although an effective renal-sparing procedure, embolization most often is associated with an inflammatory response that causes significant fever and pain that can last for several days despite the use of acetaminophen.
  • Reported cases show that 49 of 55 patients who underwent embolization developed this syndrome.
  • The use of such nonsteroidal anti-inflammatory drugs as aspirin is contraindicated because of their adverse effects on platelet function.
  • Nine patients underwent this pharmacological intervention, and one patient abstained.
  • Only two patients treated with steroids developed fever, which was assuaged with acetaminophen, and no patient reported pain.
  • [MeSH-major] Angiomyolipoma / therapy. Catheter Ablation / adverse effects. Embolization, Therapeutic / adverse effects. Kidney Neoplasms / therapy
  • [MeSH-minor] Acetaminophen / administration & dosage. Acetaminophen / therapeutic use. Adult. Analgesics, Non-Narcotic / administration & dosage. Analgesics, Non-Narcotic / therapeutic use. Angiography / methods. Drug Administration Schedule. Female. Humans. Inflammation / prevention & control. Injections, Intravenous. Kidney Diseases / therapy. Male. Syndrome. Tuberous Sclerosis / therapy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 by the National Kidney Foundation, Inc.
  • (PMID = 11979340.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 362O9ITL9D / Acetaminophen
  • [Number-of-references] 40
  •  go-up   go-down


11. Schroeder M, Aul C: [Anti-angiogenic therapy of a renal angiomyolipoma in a seriously disabled patient suffering from multiple sclerosis]. Aktuelle Urol; 2005 Sep;36(5):430-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anti-angiogenic therapy of a renal angiomyolipoma in a seriously disabled patient suffering from multiple sclerosis].
  • [Transliterated title] Antiangiogenetische Therapie eines Nieren-Angiomyolipoms bei einer schwerstbehinderten Patientin mit Multipler Sklerose.
  • INTRODUCTION: Angiomyolipoma, although rare, belong together with oncocytomas to the most common benign renal neoplasms.
  • Although angiomyolipoma is usually a non-invasive tumor that does not metastasize, chirurgical intervention, especially in case of large or enlarging tumors, is recommended due to their capacity to cause haemorrhage and other significant clinical complications.
  • CASE REPORT: We report the case of a renal angiomyolipoma in a female patient seriously disabled by multiple sclerosis with reduced physical and nutritional condition.
  • The woman already underwent a nephrectomy 20 years ago due to an angiomyolipoma of the opposite kidney.
  • By a four-weekly course of EGFR-inhibitor gefitinib (Iressa), we achieved a control of the angiomyolipoma and were able to prevent nephrectomy.
  • CONCLUSIONS: The use of EGFR inhibitors, whose anti-proliferative activity in renal cell tumors derives not only from direct inhibition of cell proliferation, but also from the inhibition of angiogenesis, requires further investigation.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Angiomyolipoma / drug therapy. Antineoplastic Agents / therapeutic use. Kidney Neoplasms / drug therapy. Multiple Sclerosis / complications. Neoplasms, Second Primary / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Administration, Oral. Female. Humans. Middle Aged. Nephrectomy. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16163606.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


12. Yokoo H, Isoda K, Nakazato Y, Nakayama Y, Suzuki Y, Nakamura T, Shinkai H, Aiba M: Retroperitoneal epithelioid angiomyolipoma leading to fatal outcome. Pathol Int; 2000 Aug;50(8):649-54
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal epithelioid angiomyolipoma leading to fatal outcome.
  • Epithelioid angiomyolipoma (AML) is a newly established variant of AML, characterized by monomorphous epithelioid cells that show HMB-45 immunopositivity, and it often displays aggressive behavior.
  • To date, they have mostly appeared in the kidneys; however, the present autopsy case of a 43-year-old female without the stigmata of tuberous sclerosis complex had a huge retroperitoneal mass, accompanied by involvement of the regional lymph nodes.
  • In spite of curative surgery and repeated radio- and chemotherapy, the tumor continued to grow and brought about the patient's death 4 years after the initial symptoms.
  • [MeSH-major] Angiomyolipoma / pathology. Epithelioid Cells / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Carboplatin / therapeutic use. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Fatal Outcome. Female. Humans. Immunohistochemistry. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / chemistry. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10972864.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 7GR28W0FJI / Dacarbazine; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


13. Morton JM, McLean C, Booth SS, Snell GI, Whitford HM: Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. J Heart Lung Transplant; 2008 Apr;27(4):462-5
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment.
  • Computed tomography (CT) scan demonstrated no pulmonary abnormality, but identified a retroperitoneal mass confirmed as angiomyolipoma by CT-guided core biopsy.
  • Based on experimental work that rapamycin may inhibit angiomyolipoma cells, we commenced the patient on low-dose rapamycin.
  • [MeSH-major] Angiomyolipoma / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Lung Neoplasms / surgery. Lung Transplantation. Lymphangioleiomyomatosis / surgery. Neoplasms, Second Primary. Retroperitoneal Neoplasms / drug therapy. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Biopsy. Dose-Response Relationship, Drug. Female. Humans. Postoperative Period. Surgery, Computer-Assisted. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lymphangioleiomyomatosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Heart Lung Transplant. 2008 Nov;27(11):1268 [18971103.001]
  • (PMID = 18374885.001).
  • [ISSN] 1557-3117
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


14. Yu W, Fraser RB, Gaskin DA, Fernandez CV, Wright JR Jr: C-Kit-positive metastatic malignant pigmented clear-cell epithelioid tumor arising from the kidney in a child without tuberous sclerosis. Ann Diagn Pathol; 2005 Dec;9(6):330-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-Kit-positive metastatic malignant pigmented clear-cell epithelioid tumor arising from the kidney in a child without tuberous sclerosis.
  • We report the first pediatric case of malignant pigmented epithelioid clear-cell tumor arising from kidney; the lesion occurred in a 12-year-old girl without tuberous sclerosis.
  • The tumor was widely metastatic to the retroperitoneum and chest, and the patient died of the disease 9 months after diagnosis, despite active chemotherapy.
  • Pigmented epithelioid clear-cell tumor of the kidney is a rare variant of epithelioid angiomyolipoma and a member of the family of perivascular epithelioid cell tumors (PEComas).
  • The tumor demonstrated overlapping features between clear-cell sugar tumor and epithelioid variant of angiomyolipoma.
  • [MeSH-major] Angiomyolipoma / metabolism. Kidney Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308163.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


15. Zhang J, Kang SK, Wang L, Touijer A, Hricak H: Distribution of renal tumor growth rates determined by using serial volumetric CT measurements. Radiology; 2009 Jan;250(1):137-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of renal tumor growth rates determined by using serial volumetric CT measurements.
  • PURPOSE: To retrospectively determine the distribution of growth rates across different sizes and subtypes of renal cortical tumors by assessing tumor volume and maximum tumor diameter at serial volumetric computed tomographic (CT) examinations.
  • Fifty-three of 2304 patients (34 men, 19 women; mean age, 67 years +/- 10 [standard deviation; range, 39-88 years) who underwent nephrectomy from 1989 to 2006 did not receive preoperative chemotherapy or radiation therapy and underwent at least two preoperative contrast material-enhanced CT examinations (at least 3 months apart) with identical section thickness that was no more than one-fifth of longitudinal tumor diameter.
  • Reciprocal of doubling time (DT) (RDT) was calculated.
  • RESULTS: Thirty-two clear cell carcinomas, 10 papillary carcinomas, six chromophobe carcinomas, four oncocytomas, and one angiomyolipoma were analyzed.
  • DT ranged from -78476.54 to 18057.43 days (mean, -1230.73 days; median, 590.51 days).
  • Small renal tumors (<or=3.5 cm) were similar to larger tumors in subtype and growth rate.
  • Age at diagnosis correlated negatively with renal tumor growth rate (P = .03).
  • CONCLUSION: Growth rates in renal tumors of different sizes, subtypes, and grades represent a wide range and overlap substantially.
  • Small renal tumors appear to be similar to larger ones in nature.
  • [MeSH-major] Cone-Beam Computed Tomography / methods. Kidney Cortex / radiography. Kidney Neoplasms / radiography
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / radiography. Adenoma, Oxyphilic / surgery. Adult. Aged. Aged, 80 and over. Angiomyolipoma / pathology. Angiomyolipoma / radiography. Angiomyolipoma / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radiography. Carcinoma, Papillary / surgery. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / radiography. Carcinoma, Renal Cell / surgery. Disease Progression. Female. Humans. Male. Mathematical Computing. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Tumor Burden

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • [CommentIn] Radiology. 2013 Dec;269(3):949-50 [24261507.001]
  • [CommentIn] Radiology. 2009 Jul;252(1):314; author reply 314-5 [19561267.001]
  • [ErratumIn] Radiology. 2013 Dec;269(3):950
  • [ErratumIn] Radiology. 2009 Jul;252(1):318
  • (PMID = 19092093.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Micozkadioglu H, Koc Z, Ozelsancak R, Yildiz I: Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient. Ren Fail; 2010;32(10):1233-6
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
  • Tuberous sclerosis complex (TSC) is an inherited multisystem disorder; it may involve kidney, brain, skin, lungs, and liver.
  • Radiologic examination revealed additional brain and renal lesions consisting of tumors, cysts, and angiomyolipomas.
  • Treatment with rapamycin disclosed improvement in skin lesions.
  • During the ninth month of treatment, magnetic resonance imaging was repeated for renal and brain lesions.
  • Imaging results showed reduction in tumor and angiomyolipoma volumes.
  • Oral rapamycin therapy can improve renal, brain, and skin lesions in TSC disease.
  • Therefore, it may be an alternative therapy for TSC patients.
  • [MeSH-major] Brain Neoplasms / drug therapy. Immunosuppressive Agents / therapeutic use. Kidney Neoplasms / drug therapy. Sirolimus / therapeutic use. Skin Neoplasms / drug therapy. Tuberous Sclerosis / complications
  • [MeSH-minor] Adult. Angiofibroma / drug therapy. Angiofibroma / etiology. Facial Neoplasms / drug therapy. Female. Humans. Magnetic Resonance Imaging


17. Benden C, Rea F, Behr J, Corris PA, Reynaud-Gaubert M, Stern M, Speich R, Boehler A: Lung transplantation for lymphangioleiomyomatosis: the European experience. J Heart Lung Transplant; 2009 Jan;28(1):1-7
MedlinePlus Health Information. consumer health - Lung Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lung transplantation has been accepted widely as therapy for end-stage pulmonary lymphangioleiomyomatosis (LAM); however, single-center and national experience is limited due to the rarity of LAM.
  • LAM-related complications included renal angiomyolipoma and pneumothorax in the native lung.
  • [MeSH-minor] Adult. Cause of Death. Drug Therapy, Combination. Europe. Exercise Test. Female. Forced Expiratory Volume. Humans. Immunosuppressive Agents / therapeutic use. Intraoperative Complications / classification. Intraoperative Complications / epidemiology. Lung Diseases / epidemiology. Respiratory Function Tests. Surveys and Questionnaires. Survival Analysis. Tissue Adhesions / epidemiology. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphangioleiomyomatosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19134523.001).
  • [ISSN] 1557-3117
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


18. Okoń K: Pathology of renal tumors in adults. Molecular biology, histopathological diagnosis and prognosis. Pol J Pathol; 2008;59(3):129-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of renal tumors in adults. Molecular biology, histopathological diagnosis and prognosis.
  • Malignant renal tumors constitute 3% of human cancers, although their frequency differs greatly in various areas.
  • Since the fifties, the incidence of renal cancers has been increasing, but at the some time the prognosis has been improving.
  • In particular, in the last years, several new treatment modalities have been introduced, relying on the understanding of renal cancer biology.
  • The identified etiological factors include smoking, increased body mass, dietary factors and chronic renal disease.
  • There are several renal tumor types differing in morphology, molecular genetics and biology.
  • At least two types of papillary carcinomas exist, which have different morphology and prognosis.
  • Differential diagnosis of these tumors is particularly difficult and may require extensive immunohistochemical and molecular studies.
  • Some renal tumors have been described or recognized only relatively recently; these newer entities include multilocular cystic clear cell carcinoma, spindle cell papillary mucinous carcinoma, tubulocystic carcinoma, renal epithelial and stromal tumor, epithelioid and oncocytic angiomyolipoma.
  • The improved prognosis in renal cancer depends on earlier detection, but also on refinement of therapeutic methods.
  • Renal carcinoma is notorious for its low sensitivity to chemotherapy and radiotherapy.
  • For several years, immunological treatment with IL-2 and INF-alpha was the only adjuvant therapy method.
  • However, recently several new drugs have been introduced; they act on tyrosine-kinase receptors, VEGF, c-Met or mTOR pathway.
  • With this progress, perfect understanding of renal tumor biology and exact histological diagnosis have become of prime practical importance.
  • [MeSH-major] Kidney Neoplasms


19. Miniati D, Gay AN, Parks KV, Naik-Mathuria BJ, Hicks J, Nuchtern JG, Cass DL, Olutoye OO: Imaging accuracy and incidence of Wilms' and non-Wilms' renal tumors in children. J Pediatr Surg; 2008 Jul;43(7):1301-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging accuracy and incidence of Wilms' and non-Wilms' renal tumors in children.
  • PURPOSE: The purpose of this study is to determine the actual incidence, age distribution, and preoperative imaging accuracy of non-Wilms' tumors (nWT) in children with renal masses.
  • METHODS: Pathologic reports from all tumor nephrectomies or open renal biopsies performed at a single institution from September 1999 to June 2005 were analyzed.
  • The nWT group included congenital mesoblastic nephroma (5), clear cell sarcoma (4), neuroblastoma (4), renal cell carcinoma (4), lymphoma (2), angiomyolipoma (2), teratoma (1), hemangioma (1), and renal epithelial tumor (1).
  • Sensitivity, specificity, positive predictive value, and negative predictive value for computed tomography (CT) determining a diagnosis of WT were 0.92, 0.55, 0.84, and 0.73, respectively.
  • The CT reports explicitly stated a potential diagnosis in 89% of cases, with a diagnostic accuracy of 82%.
  • CONCLUSIONS: Non-Wilms' tumors may represent a significant proportion of renal tumors in children, especially in children aged less than 6 months or greater than 12 years.
  • These data have significant implications for parental counseling, surgical plan, and the choice of neoadjuvant chemotherapy and argue in favor of obtaining a tissue diagnosis before instituting therapy.
  • [MeSH-major] Kidney / pathology. Kidney Neoplasms / diagnosis. Wilms Tumor / diagnosis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18639686.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Zderic SA: Renal and adrenal tumors in children. Urol Clin North Am; 2004 Aug;31(3):607-17, xi
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal and adrenal tumors in children.
  • Survival rates for children with kidney tumors approach 90% for even the most advanced stages of disease, but the surgical management of large lesions remains challenging.
  • With the development of additional chemotherapeutic regimens and the use of radiation therapy, survival rates have improved dramatically.
  • The National Wilms' Tumor Study has conducted four long-term studies addressing how adjunctive therapy may be tailored optimally to maximize survival and minimize the exposure to chemotherapy and radiation therapy.
  • [MeSH-major] Adrenal Gland Neoplasms / therapy. Kidney Neoplasms / therapy
  • [MeSH-minor] Adrenocortical Carcinoma / diagnosis. Angiomyolipoma / diagnosis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Clinical Trials as Topic. Combined Modality Therapy. Denys-Drash Syndrome / diagnosis. Humans. Neoplasm Staging. Nephrectomy. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy. Tomography, X-Ray Computed. Wilms Tumor / drug therapy. Wilms Tumor / pathology. Wilms Tumor / radiography. Wilms Tumor / surgery

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313069.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Sasaki N, Ando Y, Kusano E, Asano Y: A case of erythropoietin induced hypertension in a bilaterally nephrectomized patient. ASAIO J; 2003 Jan-Feb;49(1):131-5
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recombinant human erythropoietin (r-HuEPO) is an established tool for correction of renal anemia.
  • In this case, hemodialysis was started after removal of both kidneys because of rupture of an angiomyolipoma.
  • Although mean blood pressure (BP) did not change during the period of rapid correction of renal anemia by blood transfusion, treatment with r-HuEPO significantly increased mean BP.
  • These results suggested that r-HuEPO caused an elevation in BP in the absence of kidneys, and the elevation in BP was thought to be independent of an increase in hematocrit level or hypervolemia.
  • [MeSH-major] Anemia / drug therapy. Erythropoietin / adverse effects. Hypertension, Renal / chemically induced. Nephrectomy
  • [MeSH-minor] Blood Pressure / drug effects. Blood Pressure / physiology. Blood Viscosity. Humans. Male. Middle Aged. Recombinant Proteins. Renal Dialysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12558321.001).
  • [ISSN] 1058-2916
  • [Journal-full-title] ASAIO journal (American Society for Artificial Internal Organs : 1992)
  • [ISO-abbreviation] ASAIO J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin
  •  go-up   go-down


22. Hofbauer GF, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wüthrich RP, Serra AL: The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol; 2008 Aug;159(2):473-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with an incidence of approximately one in 6000.
  • We report a patient with TSC with recurrent life-threatening haemorrhage from both kidneys due to extensive angiomyolipoma formation leading to bilateral nephrectomy and renal transplantation.
  • Immunosuppressive treatment with rapamycin, a specific mTOR inhibitor, initiated because of renal transplantation, reduced facial angiofibroma dramatically.
  • [MeSH-major] Angiofibroma / drug therapy. Facial Neoplasms / drug therapy. Sirolimus / therapeutic use. Skin Neoplasms / drug therapy. Tuberous Sclerosis / complications
  • [MeSH-minor] Adolescent. Antibiotics, Antineoplastic / therapeutic use. Female. Humans. Protein Kinase Inhibitors / therapeutic use. Protein Kinases / physiology. TOR Serine-Threonine Kinases


23. Marazuela M, Domínguez-Gadea L, Larrañaga E, Rodríguez-Ramos R, López-Gallardo G, Rodríguez-Eyre JL, Gómez-Pan A: [The use of suprarenal scintigraphy in the differential diagnosis of suprarenal incidentaloma]. Rev Clin Esp; 2005 Jul;205(7):316-21
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of suprarenal scintigraphy in the differential diagnosis of suprarenal incidentaloma].
  • OBJECTIVES: To assess the usefulness of adrenal scintigraphy for clinical evaluation of adrenal incidentalomas, and its relation with pathological diagnosis and follow-up.
  • The lesions were discovered with abdominal computerized tomography in the study of a primary tumor (22%) or in the evaluation of benign pathology (78%).
  • RESULTS: Of 46 adrenal lesions, seven didn't show uptake (three metastases, one cyst, one adrenal carcinoma, one pheochromocytoma, and one angiomyolipoma), 34 showed excessive uptake (29 nonfunctional adrenal nodules and 5 hyperfunctional adrenal nodules), and five had normal uptake (nonfunctional adrenal nodules).
  • Adrenal scintigraphy was compatible in all cases with cytological study or the response to chemotherapy.
  • CONCLUSIONS: Detection of a lesion with no uptake in adrenal scintigraphy forces to carry out complementary explorations in order to rule out malignant pathology.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029757.001).
  • [ISSN] 0014-2565
  • [Journal-full-title] Revista clínica española
  • [ISO-abbreviation] Rev Clin Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


24. Peces R, Peces C, Cuesta-López E, Pérez-Dueñas V, Vega-Cabrera C, Azorín S, Selgas R: Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex. Nephrol Dial Transplant; 2010 Nov;25(11):3787-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
  • Tuberous sclerosis complex (TSC) is caused by constitutively activated mammalian target of rapamycin (mTOR) resulting in non-malignant tumours of several organs including renal angiomyolipomas (AMLs).
  • AMLs may originate renal failure, hypertension and spontaneous life-threatening bleeding.
  • A 40-year-old man with sporadic TSC and a history of spontaneous bleeding from his left kidney AMLs received low-dose rapamycin for 12 months, and this was associated with a reduction in bilateral kidney AML volume, stabilization and even improvement of renal function.
  • There was also a reduction of facial angiofibromas, improvement of blood pressure control and absence of AML bleeding over this time period.
  • To the best of our knowledge, this is the first report of a case of reduction in renal AML volume together with preservation of renal function in a patient with TSC receiving low-dose rapamycin.
  • [MeSH-major] Angiomyolipoma / drug therapy. Kidney Neoplasms / drug therapy. Sirolimus / therapeutic use. TOR Serine-Threonine Kinases / antagonists & inhibitors. Tuberous Sclerosis / drug therapy
  • [MeSH-minor] Adult. Humans. Kidney / pathology. Kidney / physiopathology. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20663789.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


25. Krischock L, Beach R, Taylor J: Sirolimus and tuberous sclerosis-associated renal angiomyolipomas. Arch Dis Child; 2010 May;95(5):391-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
  • Tuberous sclerosis, caused by germline mutations in the TSC1 or TSC2 genes, is associated with aberrant upregulation of the mammalian target of rapamycin (mTOR) signalling pathway, resulting in growth of tumours, including renal angiomyolipomas (AMLs).
  • AMLs may cause hypertension, renal failure and spontaneous life-threatening haemorrhage.
  • More recently, mTOR inhibitors have been used as molecularly targeted treatment to treat AMLs.
  • We present here the case of a paediatric patient with TSC in whom sirolimus has been used successfully to halt growth of renal AMLs.
  • [MeSH-major] Angiomyolipoma / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Kidney Neoplasms / drug therapy. Sirolimus / therapeutic use. Tuberous Sclerosis / complications

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20457704.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


26. Rigby H, Yu W, Schmidt MH, Fernandez CV: Lack of response of a metastatic renal perivascular epithelial cell tumor (PEComa) to successive courses of DTIC based-therapy and imatinib mesylate. Pediatr Blood Cancer; 2005 Aug;45(2):202-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of response of a metastatic renal perivascular epithelial cell tumor (PEComa) to successive courses of DTIC based-therapy and imatinib mesylate.
  • Subsequent investigations led to the diagnosis of metastatic perivascular epithelioid cell tumor (PEComa) arising from the left kidney.
  • Effective treatment for this rare tumor is not yet known.
  • The tumor did not respond to an initial treatment of two cycles of a dacarbazine (DTIC) based regimen.
  • She was placed on a trial of imatinib mesylate based on tumor expression of c-KIT, a tyrosine kinase targeted by this drug.
  • Lack of response and adverse effects of the drug required discontinuation of therapy.
  • [MeSH-major] Angiomyolipoma / drug therapy. Antineoplastic Agents / therapeutic use. Epithelioid Cells / pathology. Kidney Neoplasms / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Child. Dacarbazine / therapeutic use. Fatal Outcome. Female. Humans. Imatinib Mesylate. Neoplasm Metastasis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15704192.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 7GR28W0FJI / Dacarbazine; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


27. Barkagan ZS, Mamaev AN, Tsyvkina LP, Mamaeva IV: [Laboratory monitoring of recombinant factor VIIA effects]. Klin Lab Diagn; 2007 May;(5):23-5
MedlinePlus Health Information. consumer health - Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Blood Loss, Surgical / prevention & control. Factor VII / therapeutic use. Hemorrhage / drug therapy. Hemostatics / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Angiomyolipoma / complications. Angiomyolipoma / surgery. Blood Coagulation Tests. Colonic Neoplasms / complications. Colonic Neoplasms / surgery. Factor VIIa. Female. Humans. Kidney Neoplasms / complications. Kidney Neoplasms / surgery. Male. Middle Aged. Prostatic Neoplasms / complications. Prostatic Neoplasms / surgery. Recombinant Proteins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17665615.001).
  • [ISSN] 0869-2084
  • [Journal-full-title] Klinicheskaia laboratornaia diagnostika
  • [ISO-abbreviation] Klin. Lab. Diagn.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Hemostatics; 0 / Recombinant Proteins; 0 / recombinant FVIIa; 9001-25-6 / Factor VII; EC 3.4.21.21 / Factor VIIa
  •  go-up   go-down


28. Wolff N, Kabbani W, Bradley T, Raj G, Watumull L, Brugarolas J: Sirolimus and temsirolimus for epithelioid angiomyolipoma. J Clin Oncol; 2010 Feb 10;28(5):e65-8
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sirolimus and temsirolimus for epithelioid angiomyolipoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048172.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K08 NS051843; United States / NINDS NIH HHS / NS / NS051843-05; United States / NINDS NIH HHS / NS / K08 NS051843-05; United States / NINDS NIH HHS / NS / K08NS051843
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 624KN6GM2T / temsirolimus; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


29. Maleux G, Vaninbroukx J, Heye S, van Cutsem E, Oyen R: Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy. Acta Oncol; 2010 Aug;49(6):864-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.
  • [MeSH-major] Aneurysm / chemically induced. Angiogenesis Inhibitors / adverse effects. Angiomyolipoma / drug therapy. Antibodies, Monoclonal / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / pathology. Kidney Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Aneurysms.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20230212.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


30. Wen MC, Jan YJ, Li MC, Wang J, Lin A: Monotypic epithelioid angiomyolipoma of the liver with TFE3 expression. Pathology; 2010 Apr;42(3):300-2
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monotypic epithelioid angiomyolipoma of the liver with TFE3 expression.
  • [MeSH-major] Angiomyolipoma / metabolism. Angiomyolipoma / pathology. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / biosynthesis. Liver Neoplasms / metabolism. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunohistochemistry. Lymphoma, Large B-Cell, Diffuse / drug therapy. Male. Neoplasms, Second Primary / metabolism. Neoplasms, Second Primary / pathology. Prednisone / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350230.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Biomarkers, Tumor; 0 / TFE3 protein, human; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


31. Krishnan A, Sandrini A, Yates D: Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. J Heart Lung Transplant; 2008 Nov;27(11):1268
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment.
  • [MeSH-major] Angiomyolipoma / drug therapy. Immunosuppressive Agents / therapeutic use. Lung Transplantation / adverse effects. Sirolimus / therapeutic use

  • Genetic Alliance. consumer health - Lymphangioleiomyomatosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Heart Lung Transplant. 2008 Apr;27(4):462-5 [18374885.001]
  • (PMID = 18971103.001).
  • [ISSN] 1557-3117
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


32. Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, Doyle T, Elmslie F, Saggar A, de Vries PJ, Sampson JR: Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med; 2008 Jan 10;358(2):200-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.
  • [MeSH-major] Angiomyolipoma / drug therapy. Immunosuppressive Agents / therapeutic use. Kidney Diseases / drug therapy. Lymphangioleiomyomatosis / complications. Protein Kinase Inhibitors / therapeutic use. Sirolimus / therapeutic use. Tuberous Sclerosis / complications


33. Paul E, Thiele E: Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis. N Engl J Med; 2008 Jan 10;358(2):190-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Lung Neoplasms / drug therapy. Lymphangioleiomyomatosis / drug therapy. Sirolimus / therapeutic use. Tuberous Sclerosis / drug therapy
  • [MeSH-minor] Angiomyolipoma / drug therapy. Humans. Kidney Diseases / drug therapy. Protein Kinase Inhibitors / therapeutic use. Protein Kinases / metabolism. Respiratory Function Tests. TOR Serine-Threonine Kinases. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Lymphangioleiomyomatosis.
  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2008 Jan 10;358(2):140-51 [18184959.001]
  • (PMID = 18184966.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Protein Kinase Inhibitors; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down






Advertisement